Kisplyx (lenvatinib), in combination with everolimus, received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor targeted therapy. The opinion was based on results from a phase II trial that showed...
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
